



EUROPEAN  
COMMISSION

Brussels, 26.4.2019  
C(2019) 3346 (final)

**COMMISSION IMPLEMENTING DECISION**

**of 26.4.2019**

**granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "ReproCyc ParvoFLEX - Porcine parvovirus vaccine (inactivated)", a veterinary medicinal product**

(Text with EEA relevance)

(ONLY THE GERMAN TEXT IS AUTHENTIC)

# COMMISSION IMPLEMENTING DECISION

of 26.4.2019

**granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "ReproCyc ParvoFLEX - Porcine parvovirus vaccine (inactivated)", a veterinary medicinal product**

(Text with EEA relevance)

(ONLY THE GERMAN TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>1</sup>, and in particular Article 35(2) thereof,

Having regard to the application submitted by Boehringer Ingelheim Vetmedica GmbH, on 22 March 2018, under Article 4(1) of Regulation (EC) No 726/2004,

Having regard to the opinion of the European Medicines Agency, formulated on 21 February 2019 by the Committee for Medicinal Products for Veterinary Use,

Whereas:

- (1) The medicinal product "ReproCyc ParvoFLEX - Porcine parvovirus vaccine (inactivated)" complies with the requirements set out in Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products<sup>2</sup>.
- (2) It is therefore appropriate to authorise its placing on the market.
- (3) The Committee for Medicinal Products for Veterinary Use considered that "porcine parvovirus strain 27a viral protein 2" is a new active substance.
- (4) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee for Veterinary Medicinal Products,

HAS ADOPTED THIS DECISION:

## *Article 1*

The marketing authorisation provided for in Article 3 of Regulation (EC) No 726/2004 is granted for the medicinal product "ReproCyc ParvoFLEX - Porcine parvovirus vaccine (inactivated)", the characteristics of which are summarised in Annex I to this Decision.

---

<sup>1</sup> OJ L 136, 30.4.2004, p. 1.

<sup>2</sup> OJ L 311, 28.11.2001, p. 1.

"ReproCyc ParvoFLEX - Porcine parvovirus vaccine (inactivated)" shall be registered in the Union Register of Medicinal Products under number EU/2/19/237.

*Article 2*

The marketing authorisation concerning the medicinal product referred to in Article 1 shall be subject to compliance with the conditions set out in Annex II and, in particular, with those relating to manufacture and importation, control and issue.

*Article 3*

The labelling and package leaflet concerning the medicinal product referred to in Article 1 shall comply with the conditions set out in Annex III.

*Article 4*

The period of validity of the authorisation shall be five years from the date of notification of this Decision.

*Article 5*

This Decision is addressed to Boehringer Ingelheim Vetmedica GmbH, D-55216 Ingelheim am Rhein, Deutschland.

Done at Brussels, 26.4.2019

*For the Commission*

*Anne BUCHER  
Director-General*